logo
Plus   Neg
Share
Email

Pfizer To Acquire Array BioPharma In $11.4 Bln Deal - Quick Facts

Pfizer Inc. (PFE) agreed Monday to acquire Array BioPharma Inc. (ARRY) for $48 per share in cash, for a total enterprise value of about $11.4 billion. The Boards of Directors of both companies have approved the merger. Pfizer expects to complete the acquisition in the second half of 2019.

Array is a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.

The proposed deal strengthens Pfizer's biopharmaceutical business and expands its pipeline with multiple high-potential targeted investigational cancer therapies, adding a large portfolio of royalty-generating out-licensed medicines.

Array's portfolio includes the approved combined use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma. It is currently being investigated in over 30 clinical trials across several solid tumor indications, including the Phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer (mCRC).

The deal also sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers.

Upon the close of the transaction, Array's employees will join Pfizer and continue to be located in Cambridge, Massachusetts and Morrisville, North Carolina, as well as Boulder, Colorado, which becomes part of Pfizer's Oncology Research & Development network in addition to La Jolla, California and Pearl River, New York. Pfizer plans to maintain Array's highly productive research unit in Boulder to complement its research hubs.

Pfizer expects to finance the majority of the transaction with debt and the balance with existing cash. The transaction is expected to be dilutive to Pfizer's adjusted earnings per share by $0.04 -$0.05 in 2019, $0.04 -$0.05 in 2020, neutral in 2021, and accretive beginning in 2022, with additional accretion and growth anticipated thereafter.

Pfizer said it will provide any appropriate updates to its current 2019 guidance in conjunction with its third quarter 2019 earnings release.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup. The U.S. Department of Justice said it settled with a Florida-based IT recruiting and staffing company for immigration-related discrimination against non-U.S. citizens, including asylees. Perspective Talent LLC, a Pembroke Pines company, was found by the DOJ to have posted discriminatory job advertisements that unlawfully excluded individuals who are authorized to work in the U.S.
Follow RTT
>